{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Buechel M"],"funding":["Clovis","Tesaro","Caris","Takeda","J &amp; J","Pfizer","OncoMed","AbbVie","Merck","Novartis","Roche","PTC Therapeutics","Janssen","NCI NIH HHS","AstraZeneca","Lilly","Esperance","Roche/Genentech"],"pagination":["721-732"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8887593"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(5)"],"pubmed_abstract":["<h4>Background</h4>Ovarian cancer remains the most deadly gynecologic cancer with the majority of patients relapsing within 3 years of diagnosis. Traditional treatment paradigms linked to platinum sensitivity or resistance are currently being questioned in the setting of new diagnostic methods and treatment options.<h4>Design</h4>Authors carried out review of the literature on key topics in treatment of recurrent epithelial ovarian cancer (EOC) when platinum is still an option; including secondary surgical cytoreduction, chemotherapy, novel treatment options, and maintenance therapy. A treatment algorithm is proposed.<h4>Results</h4>Molecular characterization of EOC is critical to help guide treatment decisions. The role of secondary cytoreductive surgery is currently being evaluated with "],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pubmed_title":["Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option."],"pmcid":["PMC8887593"],"funding_grant_id":["P50 CA217685"],"pubmed_authors":["Monk BJ","Westin SN","Buechel M","Coleman RL","Herzog TJ","Moore KN"],"additional_accession":[]},"is_claimable":false,"name":"Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.","description":"<h4>Background</h4>Ovarian cancer remains the most deadly gynecologic cancer with the majority of patients relapsing within 3 years of diagnosis. Traditional treatment paradigms linked to platinum sensitivity or resistance are currently being questioned in the setting of new diagnostic methods and treatment options.<h4>Design</h4>Authors carried out review of the literature on key topics in treatment of recurrent epithelial ovarian cancer (EOC) when platinum is still an option; including secondary surgical cytoreduction, chemotherapy, novel treatment options, and maintenance therapy. A treatment algorithm is proposed.<h4>Results</h4>Molecular characterization of EOC is critical to help guide treatment decisions. The role of secondary cytoreductive surgery is currently being evaluated with ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 May","modification":"2025-04-18T12:09:44.086Z","creation":"2025-04-06T21:48:58.377Z"},"accession":"S-EPMC8887593","cross_references":{"pubmed":["30887020"],"doi":["10.1093/annonc/mdz104"]}}